美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

bioAffinity Technologies Equity Warrants Exp 23 June 2027 Warrant

0.3200

+0.030010.34%

成交量：1,217

成交額：372.28

市值：911.00萬

市盈率：-0.02

高：0.3200

開：0.3200

低：0.2615

收：0.2900

52周最高：0.9800

52周最低：0.0101

股本：2,846.86萬

流通股本：2,846.86萬

量比：0.15

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-20.7379

淨資產收益率：-1860.15%

總資產收益率：-125.11%

市淨率：2.42

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

bioAffinity Technologies宣佈其Cypath® Lung非侵入性肺癌診斷技術獲香港專利授權

bioAffinity Technologies宣佈1比15反向股票拆分，將於2026年8月24日開盤時生效

bioAffinity Technologies與Avmedical達成全國性聯邦醫療分銷協議，推動Cypath® Lung檢測普及

bioAffinity Technologies 宣佈完成400萬美元定向增發，按納斯達克規則市價發行

bioAffinity Technologies 宣佈完成400萬美元市價私募配售定價，符合納斯達克規則

bioAffinity Technologies公布積極臨床前結果：專有基因沉默技術選擇性殺傷鱗狀皮膚癌細胞，不損傷健康細胞

bioAffinity Technologies 宣佈獲墨西哥專利許可，涵蓋基於Cypath® Lung技術的新型肺癌檢測方法

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BIAFW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIAFW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAFW\",,,,,undefined,":{"symbol":"BIAFW","market":"US","secType":"STK","nameCN":"bioAffinity Technologies Equity Warrants Exp 23 June 2027 Warrant","latestPrice":0.32,"timestamp":1790107200000,"preClose":0.29,"halted":0,"volume":1217,"delay":0,"changeRate":0.10344827586206906,"floatShares":28468614,"shares":28468614,"eps":-20.7379,"marketStatus":"盤前交易","change":0.03,"latestTime":"09-23 06:52:25 EDT","open":0.32,"high":0.32,"low":0.2615,"amount":372.2844378,"amplitude":0.201724,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-20.7379,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1790170200000},"marketStatusCode":1,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":0.32,"postHourTrading":{"tag":"盘后","latestPrice":0.32,"preClose":0.32,"latestTime":"17:47 EDT","volume":170,"amount":44.3089,"timestamp":1790113661671,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.15010255646458154},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAFW\",,,,,undefined,":{"symbol":"BIAFW","floatShares":28468614,"roa":"-125.11%","roe":"-1860.15%","lyrEps":0,"volumeRatio":0.15010255646458154,"shares":28468614,"dividePrice":0,"high":0.32,"amplitude":0.201724,"preClose":0.29,"low":0.2615,"week52Low":0.0101,"pbRate":"2.42","psRate":"1.54","week52High":0.98,"institutionHeld":0,"latestPrice":0.32,"eps":-20.7379,"divideRate":0,"volume":1217,"delay":0,"ttmEps":-20.7379,"open":0.32,"prevYearClose":0.35,"prevWeekClose":0.3002,"prevMonthClose":0.0751,"prevQuarterClose":0.1395,"fiveDayClose":0.13,"twentyDayClose":0.0751,"sixtyDayClose":0.1402},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIAFW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"BIAFW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-08-14","symbol":"BIAFW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIAFW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIAFW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIAFW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1127268411","title":"bioAffinity Technologies宣佈其Cypath® Lung非侵入性肺癌診斷技術獲香港專利授權","url":"https://stock-news.laohu8.com/highlight/detail?id=1127268411","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127268411?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 20:01","pubTimestamp":1789646477,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies, Inc.今日宣布，公司已成功获得香港专利授权，该专利覆盖其创新的Cypath Lung非侵入性肺癌诊断技术。Cypath Lung作为一种突破性的非侵入性检测手段，旨在通过分析患者痰液样本中的细胞特征，实现对肺癌的早期筛查与诊断。随着全球对精准医疗和早期诊断需求的持续攀升，bioAffinity Technologies正凭借其差异化的技术优势，逐步构建起覆盖多区域的知识产权保护网络，旨在为全球患者提供更为高效、安全且精准的肺癌诊断解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190500452","title":"bioAffinity Technologies宣佈1比15反向股票拆分，將於2026年8月24日開盤時生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1190500452","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190500452?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 20:01","pubTimestamp":1787227281,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies, Inc.今日正式宣告，其先前披露的1比15反向股票拆分计划，已确定于2026年8月24日美股开盘之际正式落地。此举意味着，每15股现有普通股将自动合并为1股新股，公司总股本相应大幅缩减，而每股股价则按比例抬升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAFW","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123453385","title":"bioAffinity Technologies與Avmedical達成全國性聯邦醫療分銷協議，推動Cypath® Lung檢測普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1123453385","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123453385?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 20:01","pubTimestamp":1787054476,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies与Avmedical近日联合宣布，双方已签署一项覆盖全美的联邦医疗体系分销合作协议，旨在大幅拓展Cypath Lung检测产品的市场覆盖范围。这项协议的达成，意味着bioAffinity Technologies旗下核心产品Cypath Lung——一种用于肺癌早期检测的非侵入性技术——将正式进入联邦医疗系统的分销网络。双方均未透露协议的具体财务条款，但业内普遍认为，这一合作将为bioAffinity Technologies打开联邦医疗市场的大门，对其未来营收增长构成积极支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139786761","title":"bioAffinity Technologies 宣佈完成400萬美元定向增發，按納斯達克規則市價發行","url":"https://stock-news.laohu8.com/highlight/detail?id=1139786761","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139786761?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 23:08","pubTimestamp":1786720088,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies, Inc.宣告，其按照纳斯达克规则以市价定价的400万美元私募配售已正式结束。此次发行圆满收官，为公司注入了新的资金活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAFW","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130138033","title":"bioAffinity Technologies 宣佈完成400萬美元市價私募配售定價，符合納斯達克規則","url":"https://stock-news.laohu8.com/highlight/detail?id=1130138033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130138033?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 21:12","pubTimestamp":1786626754,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies, Inc. 今日正式对外宣布，其规模达400万美元的市价私募配售已成功完成定价。此次发行严格遵循纳斯达克市场规则，以现行市场价格进行交易。这是一次备受瞩目的资本运作，为公司未来发展注入了新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAFW","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176989506","title":"bioAffinity Technologies公布積極臨床前結果：專有基因沉默技術選擇性殺傷鱗狀皮膚癌細胞，不損傷健康細胞","url":"https://stock-news.laohu8.com/highlight/detail?id=1176989506","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176989506?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 20:06","pubTimestamp":1782129966,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies公司报告了积极的临床前研究结果，其专有的基因沉默技术展现出了对鳞状皮肤癌细胞的细胞毒性，同时不会对健康细胞造成伤害。这项技术显示出高度的选择性，为针对此类癌症的精准疗法开发提供了新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAFW","BIAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188716872","title":"bioAffinity Technologies 宣佈獲墨西哥專利許可，涵蓋基於Cypath® Lung技術的新型肺癌檢測方法","url":"https://stock-news.laohu8.com/highlight/detail?id=1188716872","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188716872?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883242,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies, Inc. 近日宣布，其利用Cypath® Lung技术的新型肺癌检测方法已获得墨西哥专利许可通知。\n这项专利授权覆盖了公司创新的肺癌检测技术，进一步巩固了其在癌症早期诊断领域的知识产权布局。Cypath® Lung技术旨在通过非侵入性方法，提升肺癌检测的准确性与可及性。\n此次获得墨西哥专利许可，标志着该技术在全球范围内的知识产权保护取得又一重要进展。它为bioAffinity Technologies未来在墨西哥及更广泛拉丁美洲市场的商业拓展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BIAF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}